Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China

被引:4
|
作者
Dun, Changchang [1 ,2 ]
Yuan, Meiwen [2 ]
Zhao, Xuelian [2 ]
Hu, Shangying [2 ]
Arbyn, Marc [3 ]
Zhao, Fanghui [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Dept Populat Med, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Epidemiol,Canc Hosp, Beijing, Peoples R China
[3] Sci Inst Publ Hlth, Belgian Canc Ctr, Unit Canc Epidemiol, Brussels, Belgium
来源
CANCER MEDICINE | 2024年 / 13卷 / 11期
关键词
cervical cancer; HPV genotyping; pooled analysis; screening; triage; INTRAEPITHELIAL NEOPLASIA; RISK; WOMEN; PREVALENCE; INFECTION; METAANALYSIS; PERFORMANCE;
D O I
10.1002/cam4.7316
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To assess the clinical values of extended human papillomavirus (HPV) genotyping in triage of high-risk HPV-positive women, focusing on the trade-off between cervical precancer detections and colposcopy referrals. Methods: A bivariate random-effects model was used to estimate the diagnostic accuracy of primary HPV screening with following triage strategies to detect cervical precancers: (i) partial genotyping for HPV16/18 combined with cytological testing at atypical squamous cells of undetermined significance threshold (used as the comparator), (ii) genotyping for HPV16/18/58/52, (iii) genotyping for HPV16/18/58/52/33, (iv) genotyping for HPV16/18/58/33/31, (v) genotyping for HPV16/18/58/52/33/31, and (vi) genotyping for HPV16/18/58/52/33/31/39/51. Internal risk benchmarks for clinical management were used to evaluate the risk stratification of each triage strategy. Results: A total of 16,982 women (mean age 46.1 years, range 17-69) were included in this analysis. For CIN3+ detection, triage with HPV16/18/58/33/31 genotyping achieved lower positivity (6.85% vs. 7.35%, p = 0.001), while maintaining similar sensitivity (91.35% vs. 96.42%, p = 0.32) and specificity (94.09% vs. 93.67%, p = 0.56) compared with the comparator strategy. Similar patterns were observed for CIN2+ detection. Women with a positive HPV16/18/58/33/31 genotyping test had high enough risk for CIN3+ for colposcopy referral, while the risk for women with a negative test was below the 1-year return decision threshold according to internal benchmarks. Conclusions: Our findings suggested extended HPV genotyping is of potential to be used as a triage technique integrated into HPV-based cervical cancer screening, leading to reduced need for colposcopy referral while maintaining similar disease detection and efficient risk stratification.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Cervical Cancer Screening with DNA-HPV Testing and Precancerous Lesions Detection: A Brazilian Population-based Demonstration Study
    Teixeira, Julio Cesar
    Vale, Diama Bhadra
    Discacciati, Michelle Garcia
    Campos, Cirbia Silva
    Braganca, Joana Froes
    Zeferino, Luiz Carlos
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2023, 45 (01): : 21 - 30
  • [42] Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study
    Gori, S.
    Battagello, J.
    Gustinucci, D.
    Campari, C.
    Zorzi, M.
    Frayle, H.
    Passamonti, B.
    Sartori, G.
    Bulletti, S.
    Fodero, C.
    Cesarini, E.
    Faggiano, R.
    Del Mistro, A.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 (08) : 1353 - 1362
  • [43] Impact of high-risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real-world data from regional cervical cancer screening program
    Rosario, Andreia
    Sousa, Ana
    Marinho-Dias, Joana
    Medeiros, Rui
    Lobo, Claudia
    Leca, Luis
    Coimbra, Nuno
    Tavares, Fernando
    Baldaque, Ines
    Martins, Gabriela
    Monteiro, Paula
    Henrique, Rui
    Sousa, Hugo
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
  • [44] HPV testing in Polish population-based cervical cancer screening programme (HIPPO project)-study protocol of a randomised healthcare policy trial
    Glinska, Patrycja
    Komerska, Katarzyna
    Janik, Beata
    Olkowicz, Julia
    Jedrzejewska, Ilona
    Macios, Anna
    Wieszczy, Paulina
    Kaminski, Michal F.
    Arbyn, Marc
    Nowakowski, Andrzej
    BMC CANCER, 2023, 23 (01)
  • [45] Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: A 9-year follow-up of a population-based screening cohort
    Valencak, Anja Ostrbenk
    Kroon, Kelsi R.
    Fabjan, Danijela
    Mlakar, Jana
    Seme, Katja
    Berkhof, Johannes
    Poljak, Mario
    INTERNATIONAL JOURNAL OF CANCER, 2025, 156 (04) : 788 - 801
  • [46] Impact of high-performance human papillomavirus testing to improve cervical cancer screening in China: a prospective population-based multicentre cohort study
    Yin, Jian
    Zhang, Shaokai
    Li, Zhifang
    Li, Yufei
    Wang, Hong
    Zhang, Xun
    Pan, Qinjing
    Chen, Wen
    Luo, Xiping
    Sun, Xibin
    Zhao, Fanghui
    Qiao, Youlin
    CLINICAL MICROBIOLOGY AND INFECTION, 2024, 30 (09) : 1190 - 1196
  • [47] Human papillomavirus (HPV) testing for cervical cancer screening in a middle-income country: comment on a large real-world implementation study in China
    Louise T. Thomsen
    Susanne K. Kjær
    BMC Medicine, 19
  • [48] Human papillomavirus (HPV) testing for cervical cancer screening in a middle-income country: comment on a large real-world implementation study in China
    Thomsen, Louise T.
    Kjaer, Susanne K.
    BMC MEDICINE, 2021, 19 (01)
  • [49] Real-world effectiveness of cytology and HPV-based screening strategy in cervical cancer screening: A cross-sectional population-based study in Chengdu, China
    Yao, Boshuang
    Peng, Jieru
    Song, Wei
    Yang, Liu
    Zhang, Meng
    Wu, Xia
    Wu, Shiyi
    Wang, Xiaoyu
    Li, Chunrong
    Yang, Chunxia
    PLOS ONE, 2024, 19 (02):
  • [50] Cost–benefit analysis of p16INK4a immunocytology and liquid-based cytology triage after primary HPV testing for cervical cancer screening in China
    Dachuang Zhou
    Jun Hou
    Jiayi Xi
    Yuan Li
    Xinfeng Qu
    Wenxi Tang
    Ruifang Wu
    Infectious Agents and Cancer, 20 (1)